TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07365462: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Sponsor: Neurocrine Biosciences · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 100 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,818,400

Rescue Site Savings

+$2,528,400

Unlock Full NCT07365462 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07365462 Rescue Dossier →